Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?
Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?
On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How?
On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How?
Prof. Gerhardt Attard, Assoc. Prof. Tanya Dorff, Prof. Fred Saad
Take the e-learning and claim your CME credit. Watch the video and download the slides.
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Prof. Fred Saad
Professor and Chairman of Urology, Director of GU Oncology Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center, Canada
Canada
BluePrint Resource | 
60 min
|accreditation:
EACCME
download resources
I agree that this educational programme:
Was valuable to me:
1/3
Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?
- The efficacy and safety profiles of PARP inhibitors for patients with prostate cancer and the safety profile in other tumour types
- Implementation of testing strategies to predict if the prostate cancer is likely to respond to a PARP inhibitor or some other treatment
- Data of combination studies with PARP inhibitors, the appropriate implementation in treatment strategies and the impact on clinical practice
Take the e-learning and claim your CME credit.
Watch the Experts Knowledge Share event and download the slides above.
Meeting Video Chapters
| Chapter 1 | 00:00 | Faculty and Disclaimer |
| Chapter 2 | 00:28 | Overview and scene-setting - Prof. Fred Saad |
| Chapter 3 | 02:08 | Who should you treat? - Prof. Gerhardt Attard |
| Chapter 4 | 18:55 | Why you should treat - Assoc. Prof. Tanya Dorff |
| Chapter 5 | 33:11 | Combination therapy with PARP inhibitors - Prof. Fred Saad |
| Chapter 6 | 46:48 | Questions for panel |
| Chapter 7 | 52:13 | Future perspectives and summary - Prof Fred Saad |
Other programmes of interest
5 min
Other programmes developed by Prof. Gerhardt Attard
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Other programmes developed by Assoc. Prof. Tanya Dorff
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
